Olema Pharmaceuticals (OLMA) Stock Price, News & Analysis

Company Overview

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for women’s cancers, with an emphasis on hormone receptor-positive breast cancer. The company’s research is centered on treatments designed to address cancer biology and resistance mechanisms that can limit the effectiveness of existing endocrine therapies.

Olema’s lead product candidate is palazestrant, an oral selective estrogen receptor degrader (SERD) being developed for patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer. The company is evaluating palazestrant in clinical studies involving patients whose disease has progressed following prior endocrine-based treatment, as well as in earlier-line treatment settings. Olema also maintains additional discovery and development programs intended to expand its oncology pipeline.

Founded in 2013 and headquartered in San Francisco, California, Olema has advanced its programs through clinical development and became a publicly traded company in 2021. The company’s leadership includes co-founder and Chief Executive Officer Sean Bohen, M.D., Ph.D., who has experience in oncology drug development and commercialization. Its clinical development activities are directed toward addressing the needs of patients with breast cancer in the United States and other markets where its studies are conducted.

Key Stats

• Today's Range: $6.92 to $7.44
• 50-Day Range: $6.41 to $10.98
• 52-Week Range: $6.24 to $36.26
• Volume: 751,097 shs
• Average Volume: 1.37 million shs
• Market Capitalization: $612.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $40.60
• Consensus Rating: Moderate Buy

Olema Pharmaceuticals Stock Analysis - MarketRank™

Olema Pharmaceuticals scored higher than 42% of companies evaluated by MarketBeat, and ranked 671st out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Olema Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on no strong buy ratings, 11 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Olema Pharmaceuticals has a consensus price target of $40.60, representing about 480.0% upside from its current price of $7.00.

Amount of Analyst Coverage

Olema Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Olema Pharmaceuticals are expected to decrease in the coming year, from ($2.43) to ($2.72) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Olema Pharmaceuticals is -3.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Olema Pharmaceuticals is -3.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Olema Pharmaceuticals has a P/B Ratio of 1.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

20.49% of the float of Olema Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Olema Pharmaceuticals has a short interest ratio ("days to cover") of 13.38, which indicates bearish sentiment.

Change versus previous month

Short interest in Olema Pharmaceuticals has recently increased by 6.69%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Olema Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Olema Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: N/A

News Sentiment

Olema Pharmaceuticals has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Olema Pharmaceuticals this week, compared to 4 articles on an average week.

Search Interest

Only 1 people have searched for OLMA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

3 people have added Olema Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Olema Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.56% of the stock of Olema Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

91.78% of the stock of Olema Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 11/01/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:OLMA
• CIK: 1750284
• Web: www.olema.com
• Phone: 650-243-5555
• Fax: N/A
• Employees: 150
• Year Founded: 2007

Price Target and Rating

• Average Price Target for Olema Pharmaceuticals: $40.60
• High Price Target: $59.00
• Low Price Target: $27.00
• Potential Upside/Downside: +480.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.77
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.12)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$162.45 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -48.26%
• Return on Assets: -43.04%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 8.86
• Quick Ratio: 8.86

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.88 per share
• Price / Book: 1.19

Miscellaneous

• Outstanding Shares: 87,500,000
• Free Float: 76,508,000
• Market Cap: $612.50 million
• Optionable: Optionable
• Beta: 2.00